The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pylorids. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 ,ug/ml; rifampin was less active, with MICs ranging from 0.25 to >1 ,g/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.
Warren and Marshall were the first to isolate Campylobacter pyloridis from the gastrointestinal mucosa of patients with peptic ulcer disease, a phenomenon that has been confirmed by other investigators (7, 9, (11) (12) (13) . Attention has subsequently focused on the susceptibility of C. pyloridis isolates to antimicrobial agents. Flores et al. determined the susceptibility to 20 antimicrobial agents of 50 isolates of Campylobacter species recovered from the gastrointestinal tracts of male homosexuals (2) . Although half of the isolates were susceptible to less than 0.06 ,tg of erythromycin per ml, drug concentrations exceeding 128 ,ug/ml were required to inhibit 90% of the isolates. Rifampin was the most active of the drugs tested. McNulty and colleagues determined the susceptibility of 70 C. pyloridis isolates to 11 antimicrobial agents (8) . Of the isolates, 90% were inhibited by 0.12 ,ug of erythromycin per ml, and all of the strains were inhibited by 0.5 ,ug/ml. Kasper rifampin were significantly higher than those of the macrolide derivatives. In vitro, erythromycin, roxithromycin, and CP 62,993 had significant activities against C. pyloridis isolates, suggesting a use for the macrolide antibiotics in the treatment of gastrointestinal infections caused by this organism. The susceptibilities of the isolates to rifampin were less consistent. Because C. pyloridis infections typically localize to the mucosa of the upper gastrointestinal tract, the successful treatment of these infections depends on the development of effective mucosal drug concentrations (5, 11) . Such studies are recommended before the initiation of clinical trials.
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